Effectiveness and safety of selective and non - selective factor Xa inhibitors in antiphospholipid syndrome and systemic lupus erythematosus: anti - Xa - activity range
- Authors: Seredavkina NV1,2, Reshetnyak TM1,2, Satybaldyeva MA1,2, Kashnikova LN1,2, Temnikova TA1,2, Nasonov EL1,2
-
Affiliations:
- V.A. Nasonova Scientific and Research Institute of Rheumatology
- Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Health of the Russian Federation
- Issue: Vol 91, No 5 (2019)
- Pages: 19-25
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33571
- DOI: https://doi.org/10.26442/00403660.2019.05.000235
- ID: 33571
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
N V Seredavkina
V.A. Nasonova Scientific and Research Institute of Rheumatology; Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Health of the Russian Federation
Email: n_seredavkina@mail.ru
к.м.н., н.с. лаб. осудистой ревматологии ФГБНУ «НИИР им. В.А. Насоновой»; ORCID: 0000-0001-5781-2964 Moscow, Russia
T M Reshetnyak
V.A. Nasonova Scientific and Research Institute of Rheumatology; Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Health of the Russian Federationд.м.н., проф., в.н.с. лаб. сосудистой ревматологии ФГБНУ «НИИР им. В.А. Насоновой»; проф. каф. ревматологии ФГБОУ ДПО РМАНПО Минздрава России Moscow, Russia
M A Satybaldyeva
V.A. Nasonova Scientific and Research Institute of Rheumatology; Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Health of the Russian Federationм.н.с. лаб. сосудистой ревматологии ФГБНУ «НИИР им. В.А. Насоновой» Moscow, Russia
L N Kashnikova
V.A. Nasonova Scientific and Research Institute of Rheumatology; Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Health of the Russian Federationк.б.н., руководитель клинико-диагностического лабораторного отд-ния ФГБНУ «НИИР им. В.А. Насоновой» Moscow, Russia
T A Temnikova
V.A. Nasonova Scientific and Research Institute of Rheumatology; Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Health of the Russian Federationврач клинико-диагностического лабораторного отд-ния ФГБНУ «НИИР им. В.А. Насоновой» Moscow, Russia
E L Nasonov
V.A. Nasonova Scientific and Research Institute of Rheumatology; Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Health of the Russian Federationакад. РАН, д.м.н., проф., научный руководитель ФГБНУ «НИИР им. В.А. Насоновой» Moscow, Russia
References
- Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004.
- Кириенко А.И., Панченко Е.П., Андрияшкин В.В. Венозный тромбоз в практике терапевта и хирурга. М.: Планида, 2012.
- Streiff M.B, Agnelli G, Connors J.M, Crowther M, Eichinger S, Lopes R, Mc Bane R.D, Moll S, Ansell J. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 2016;41(1):32-67. https://doi.org/10.1007/s11239-015-1317-0
- Решетняк Т.М. Лечение антифосфолипидного синдрома: современные стандарты. Тромбоз, гемостаз и реология. 2016;1(65):11-20.
- Babin J.L, Traylor K.L, Witt D.M. Laboratory monitoring of low - molecular - weight heparin and fondaparinux. Semin Thromb Hemost. 2017;43(3):261-9. https://doi.org/10.1055/s-0036-1581129
- Chighizola C.B, Moia M, Meroni P.L. New oral anticoagulants in thrombotic antiphospholipid syndrome. Lupus. 2014;23(12):1279-82. https://doi.org/10.1177/0961203314540968
- Сатыбалдыева М.А., Решетняк Т.М. Новые оральные антикоагулянты в терапии антифосфолипидного синдрома. Научно - практическая ревматология. 2016;54(2):219-26. http://dx.doi.org/10.14412/1995-4484-2016-219-226
- Cohen H, Hunt B.J, Efthymiou M, Arachchillage D.R, Mackie I.J, Clawson S, Sylvestre Y, Machin S.J, Bertolaccini M.L, Ruiz-Castellano M, Muirhead N, Doré C.J, Khamashta M, Isenberg D.A. RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomized, controlled, open - label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016;3(9):426-36. https://doi.org/10.1016/S2352-3026(16)30079-5
- Gladman D.D, Ibañez D, Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-91.
- Levey A.S, Stevens L.A, Schmid C.H, Zhang Y.L, Castro A.F 3rd, Feldman H.I, Kusek J.W, Eggers P, Van Lente F, Greene T, Coresh J. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.
- Miyakis S, Lockshin M.D, Atsumi T, Branch D.W, Brey R.L, Cervera R, Derksen R.H, De Groot P.G, Koike T, Meroni P.L, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos P.G, Krilis S.A. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. https://doi.org/10.1111/j.1538-7836.2006.01753.x
- Решетняк Т.М. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно - практическая ревматология. 2014;52(1):56-71. http://dx.doi.org/10. 14412/1995-4484-2014-56-71
- Bertolaccini M.L, Amengual O, Andreoli L, Atsumi T, Chighizola C.B, Forastiero R, de Groot P, Lakos G, Lambert M, Meroni P, Ortel T.L, Petri M, Rahman A, Roubey R, Sciascia S, Snyder M, Tebo A.E, Tincani A, Willis R. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014;13:917-30. https://doi.org/10.1016/j.autrev. 2014.05.001
- Pengo V, Banzato A, Denas G, Jose S.P, Bison E, Hoxha A, Ruffatti A. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev. 2013;12:832-4. https://doi.org/10.1016/j.autrev.2012.11.008
- Cередавкина Н.В., Решетняк Т.М. IX Европейский форум по антифосфолипидным антителам. Краткий обзор. Научно - практическая ревматология. 2014;52(1):115-21. http://dx.doi.org/10.14412/1995-4484-2014-115-121
- Comarmond C, Cacoub P. Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. Autoimmun Rev. 2013;12:752-7. https://doi.org/10.1016/j.autrev.2012.12.006
- Garcia D.A, Baglin T.P, Weitz J.I, Samama M.M. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence - based clinical practice guidelines. Chest. 2012;141(2 Suppl):e24S-e43S. https://doi.org/10.1378/chest.11-2291
- Turpie A.G, Bauer K.A, Eriksson B.I, Lassen M.R. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta - analysis of 4 randomized double - blind studies. Arch Intern Med. 2002;162(16):1833-40.
- Turpie A.G, Bauer K.A, Eriksson B.I, Lassen M.R. Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. Chest. 2004;126(2):501-8.
- Donath L, Lützner J, Werth S, Kuhlisch E, Hartmann A, Günther K.P, Weiss N, Beyer-Westendorf J. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry. Br J Clin Pharmacol. 2012;74(6):947-58. https://doi.org/10.1111/j.1365-2125.2012.04302.x
- Moore T.J. Optimal dosing of rivaroxaban is undefined. BMJ. 2016;355:i5549. https://doi.org/10.1136/bmj.i5549
- Joalland F, de Boysson H, Darnige L, Johnson A, Jeanjean C, Cheze S, Augustin A, Auzary C, Geffray L. Seronegative antiphospholipid syndrome, catastrophic syndrome, new anticoagulants: learning from a difficult case report. Rev Med Interne. (In French). 2014;35(11):752-6. https://doi.org/10.1016/j.revmed.2014.04.012
- Holtan S.G, Knox S.K, Tefferi A. Use of fondaparinux in a patient with antiphospholipid antibody syndrome and heparin - associated thrombocytopenia. J Thromb Haemost. 2006;4(7):1632-4. https://doi.org/ 10.1111/j.1538-7836.2006.01961.x
- Costa R, Fazal S, Kaplan R.B, Spero J, Costa R. Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis. Clin Rheumatol. 2013;32(Suppl 1):S79-82. https://doi. org/10.1007/s10067-010-1506-3
- Harenberg J. Treatment of a woman with lupus and thromboembolism and cutaneous intolerance to heparins using fondaparinux during pregnancy. Thromb Res. 2007;119(3):385-8. https://doi.org/10.1016/j.thromres.2006. 03.008
![](/img/style/loading.gif)